Research programme: anti-cancer therapeutics - Halozyme

Drug Profile

Research programme: anti-cancer therapeutics - Halozyme

Alternative Names: HTI-1511; PEG-ADA2; PEG-ADA2-E182T; PEG-ADA2-K374D; PEG-ADA2-R222Q-S265N; PEGylated adenosine deaminase 2

Latest Information Update: 23 Jul 2016

Price : $50

At a glance

  • Originator Halozyme Therapeutics
  • Class Auristatins; Drug conjugates; Enzymes
  • Mechanism of Action Adenosine deaminase inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cholangiocarcinoma; Colorectal cancer; Lung cancer; Pancreatic cancer

Most Recent Events

  • 10 May 2016 Pharmacodynamics and pharmacokinetic data from a preclinical study in Solid tumour models presented at the107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 18 Apr 2016 Preclinical trials in Cholangiocarcinoma in USA (unspecified route)
  • 18 Apr 2016 Preclinical trials in Pancreatic cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top